Open Access

[Corrigendum] TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma

  • Authors:
    • Song Ye
    • Xin-Yi Zhao
    • Xiao-Ge Hu
    • Tang Li
    • Qiu-Ran Xu
    • Huan-Ming Yang
    • Dong-Sheng Huang
    • Liu Yang
  • View Affiliations

  • Published online on: September 19, 2022     https://doi.org/10.3892/or.2022.8411
  • Article Number: 196
  • Copyright : © Ye et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

Subsequently to the publication of the above article, the authors have realized that a couple of clerical errors were made when writing the article, and wish to correct these errors in a corrigendum statement. First, in the Materials and methods section on p. 2216, the final sentence of the ʻImmunohistochemistry and tissue microarrayʼ subsection, the authors wish to add a further definition, so that the text reads as follows (changes highlighted in bold): ʻThe positive expression of RET was defined as ≥5% staining of a tumor section; high expression was defined as ≥40% staining of a tumor section, and low expression as <40%ʼ. Secondly, in the Results section, ʻMutation frequency of each gene distributed in 4 biological categoriesʼ subsection, p. 2220, right‑hand column, second paragraph, line 17, the sentence written here should have read as follows: ʻThe group with the positive expression of RET included 28.9% (26/90) of the patients, and 4 of these patients were defined as high expressionʼ.
The authors are grateful to the Editor of Oncology Reports for allowing them this opportunity to publish a corrigendum, and apologize to the readership of the journal for any inconvenience caused. [Oncology Reports 37: 2215‑2226, 2017; DOI: 10.3892/or.2017.5494]

Related Articles

Journal Cover

November-2022
Volume 48 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ye S, Zhao X, Hu X, Li T, Xu Q, Yang H, Huang D and Yang L: [Corrigendum] TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma. Oncol Rep 48: 196, 2022
APA
Ye, S., Zhao, X., Hu, X., Li, T., Xu, Q., Yang, H. ... Yang, L. (2022). [Corrigendum] TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma. Oncology Reports, 48, 196. https://doi.org/10.3892/or.2022.8411
MLA
Ye, S., Zhao, X., Hu, X., Li, T., Xu, Q., Yang, H., Huang, D., Yang, L."[Corrigendum] TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma". Oncology Reports 48.5 (2022): 196.
Chicago
Ye, S., Zhao, X., Hu, X., Li, T., Xu, Q., Yang, H., Huang, D., Yang, L."[Corrigendum] TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma". Oncology Reports 48, no. 5 (2022): 196. https://doi.org/10.3892/or.2022.8411